Gradon said F&P Healthcare is not anticipating any significant impact to its supply chain because of the coronavirus outbreak. Chinese factories have been disrupted by the restrictions, and that has flowed on to global supply chains.
F&P Healthcare doesn't have a manufacturing facility in China, although it does source raw materials from Chinese suppliers, Gradon said.
He said many suppliers expedited their supply of raw materials because F&P Healthcare makes essential medical devices.
"At this stage, we do not anticipate any significant impact on supply to our existing customers. We will continue to assess this on an ongoing basis, particularly if the outbreak escalates or continues for a prolonged period," he said.
The stock last traded at $25.20 and has lifted 13.5 per cent so far this year.